Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (311-320 of 383) with videos related to

Pageof 39
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trialLiselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2016
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab ResistanceKatrien Berns, Amir Sonnenblick, Annemiek Gennissen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
Clinical Pharmacology and Therapeutics|March 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM CohortAnna M Mc Laughlin, Thomas Helland, Fenja Klima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2018
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter TrialPatrick Neven, Lynn Jongen, Anneleen Lintermans, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Breast Cancer Research and Treatment|June 27, 2007
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative studyPatrick Neven, Robert Paridaens, Gino Pelgrims, et al.
NPJ Precision Oncology|November 6, 2025
Enhancing translational research in metastatic cancer through an open science environment: the UPTIDER experienceAnirudh Pabba, Marion Maetens, Amena Mahdami, et al.
The Lancet. Oncology|October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trialMafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Pageof 39

Showing results (311-320 of 383) with videos related to

Sort By:
Pageof 39
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trialLiselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2016
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab ResistanceKatrien Berns, Amir Sonnenblick, Annemiek Gennissen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
The Lancet. Oncology|December 9, 2022
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialStephen R D Johnston, Masakazu Toi, Joyce O'Shaughnessy, et al.
Clinical Pharmacology and Therapeutics|March 18, 2024
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM CohortAnna M Mc Laughlin, Thomas Helland, Fenja Klima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2018
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter TrialPatrick Neven, Lynn Jongen, Anneleen Lintermans, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Breast Cancer Research and Treatment|June 27, 2007
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative studyPatrick Neven, Robert Paridaens, Gino Pelgrims, et al.
NPJ Precision Oncology|November 6, 2025
Enhancing translational research in metastatic cancer through an open science environment: the UPTIDER experienceAnirudh Pabba, Marion Maetens, Amena Mahdami, et al.
The Lancet. Oncology|October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trialMafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Pageof 39